Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made another initial public offering (IPO) filing with the Hong Kong Stock Exchange, sponsored by CICC. This marks the company’s second attempt at going public on the bourse, following the failure of its first IPO attempt in June last year.
Company Background and Technology Platforms
Founded in 2001, Luzhu Biotech offers a next-generation Fab-scFv double antibody development platform called Fabite, a mammalian expression technology platform, and comprehensive biologics manufacturing infrastructure and capabilities. The company has developed multiple bacterial polysaccharide-protein conjugate vaccines and high-purity hypo-pyrogenic polysaccharide vaccines, making it the world’s first company to develop group A and C meningococcal polysaccharide conjugate vaccines.
Product Pipeline and Clinical Candidates
Luzhu Biotech’s product pipeline includes human vaccines, monoclonal antibodies (mAbs), and bispecific antibodies (BsAbs). The company has three clinical-stage product candidates: the vaccine candidate LZ901 and two candidate antibody injection products, K3 and K193.
Core Product Candidates
The core product candidate is LZ901, an in-house developed recombinant shingles vaccine candidate currently undergoing a Phase II clinical study. The company has also filed for clinical trial approval in the US. Another core product is K3, a biosimilar version of Humira (adalimumab), which has successfully concluded Phase I trials. K193, a bispecific antibody (BsAb) developed to treat B-cell leukemia and lymphoma, has demonstrated anti-tumor activity in pre-clinical studies both in vivo and in vitro.-Fineline Info & Tech
